Coverage with Evidence Development
Medicare paradigm conditioning coverage on participation in approved clinical studies or registries.
Definition
Under CED, CMS provides coverage for promising items or services on the condition that beneficiaries are enrolled in an approved study or data collection effort that addresses outstanding questions. CED is applied through an NCD, with study requirements described in CMS's CED guidance, and participating facilities must enroll patients in an approved registry or trial. Transcatheter valve replacement, linked to the TVT Registry, is a well known device example. CED decisions can be reconsidered and the study requirement removed once enough evidence exists.What this means in practice
CED is common for novel devices with developing evidence (e.g., TAVR, leadless pacemakers historically). Registry participation requirements influence hospital adoption and total cost of evidence generation.Examples
- A novel cardiac implant receives CED from CMS, requiring all patients receiving the device to be enrolled in a specific post-market registry to collect long-term outcome data.
- A new diagnostic test is covered under CED, mandating that healthcare providers submit data on patient demographics and test results to a designated database to assess its clinical utility.
- CMS grants CED for a new cancer therapy, contingent on patients participating in an approved clinical trial that aims to further evaluate its efficacy in a broader patient population.
- •Manufacturers might underestimate the resources required for data collection and study participation under CED.
- •Failing to design studies that adequately address the evidence gaps identified by CMS can lead to delays or non-coverage.
- •Misinterpreting CMS requirements for data submission and study protocols can result in compliance issues.
- •Assuming that CED implies permanent coverage without the need for submitting conclusive evidence is a common misconception.
- •Ignoring the impact of CED on market access strategies and product launch timelines can lead to commercial challenges.
Frequently asked questions
Cross-references
Related terms
Grouped by themeEditor's picks
· Hand-selected related conceptsMedicare coverage policies issued nationally (NCD) or by individual MAC contractors (LCD).
CMS pathway providing time-limited Medicare coverage for FDA-designated Breakthrough Devices.
More in Reimbursement
· Same categoryFederal program providing discounted drugs to safety-net providers.
The Medicare grouping system that determines hospital outpatient payment amounts under OPPS, analogous to MS-DRGs for inpatient.
Migration of procedures from hospitals to ambulatory surgery centers.
Financial model that estimates the total cost consequences of adopting a new technology to a payer's budget over a defined horizon.
Where this term appears across MedTech Terms.
Latest in MedTech
Sources
1 sourceSources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.
Official citation replacements checked: . Medicare documents support Medicare coding, coverage or payment context, not every payer policy or CPT editorial procedure. Citation replacement does not change the full term review date.
Inline markers like [1] jump to the matching reference above.